311 related articles for article (PubMed ID: 25803028)
1. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease.
Graham SF; Chevallier OP; Elliott CT; Hölscher C; Johnston J; McGuinness B; Kehoe PG; Passmore AP; Green BD
PLoS One; 2015; 10(3):e0119452. PubMed ID: 25803028
[TBL] [Abstract][Full Text] [Related]
2. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.
Muenchhoff J; Poljak A; Song F; Raftery M; Brodaty H; Duncan M; McEvoy M; Attia J; Schofield PW; Sachdev PS
J Alzheimers Dis; 2015; 43(4):1355-73. PubMed ID: 25159666
[TBL] [Abstract][Full Text] [Related]
3. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker.
Peña-Bautista C; Roca M; Hervás D; Cuevas A; López-Cuevas R; Vento M; Baquero M; García-Blanco A; Cháfer-Pericás C
J Proteomics; 2019 May; 200():144-152. PubMed ID: 30978462
[TBL] [Abstract][Full Text] [Related]
4. Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?
Oberacher H; Arnhard K; Linhart C; Diwo A; Marksteiner J; Humpel C
J Alzheimers Dis; 2017; 57(2):493-504. PubMed ID: 28269764
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Metabolic Signature Predisposing High Risk Patients with Mild Cognitive Impairment to Converting to Alzheimer's Disease.
Huang YL; Lin CH; Tsai TH; Huang CH; Li JL; Chen LK; Li CH; Tsai TF; Wang PN
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681563
[TBL] [Abstract][Full Text] [Related]
6. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease.
Torres LL; Quaglio NB; de Souza GT; Garcia RT; Dati LM; Moreira WL; Loureiro AP; de Souza-Talarico JN; Smid J; Porto CS; Bottino CM; Nitrini R; Barros SB; Camarini R; Marcourakis T
J Alzheimers Dis; 2011; 26(1):59-68. PubMed ID: 21593563
[TBL] [Abstract][Full Text] [Related]
7. Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression.
Yang H; Lyutvinskiy Y; Herukka SK; Soininen H; Rutishauser D; Zubarev RA
J Alzheimers Dis; 2014; 40(3):659-66. PubMed ID: 24503613
[TBL] [Abstract][Full Text] [Related]
8. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.
Trushina E; Dutta T; Persson XM; Mielke MM; Petersen RC
PLoS One; 2013; 8(5):e63644. PubMed ID: 23700429
[TBL] [Abstract][Full Text] [Related]
9. Amnestic mild cognitive impairment and conversion to Alzheimer's disease: insulin resistance and glycoxidation as early biomarker clusters.
Monacelli F; Borghi R; Cammarata S; Nencioni A; Piccini A; Tabaton M; Odetti P
J Alzheimers Dis; 2015; 45(1):89-95. PubMed ID: 25471189
[TBL] [Abstract][Full Text] [Related]
10. Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.
Leifert WR; Nguyen T; Rembach A; Martins R; Rainey-Smith S; Masters CL; Ames D; Rowe CC; Macaulay SL; François M; Fenech MF;
J Alzheimers Dis; 2015; 48(2):443-52. PubMed ID: 26402008
[TBL] [Abstract][Full Text] [Related]
11. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease.
Olazarán J; Gil-de-Gómez L; Rodríguez-Martín A; Valentí-Soler M; Frades-Payo B; Marín-Muñoz J; Antúnez C; Frank-García A; Acedo-Jiménez C; Morlán-Gracia L; Petidier-Torregrossa R; Guisasola MC; Bermejo-Pareja F; Sánchez-Ferro Á; Pérez-Martínez DA; Manzano-Palomo S; Farquhar R; Rábano A; Calero M
J Alzheimers Dis; 2015; 45(4):1157-73. PubMed ID: 25649659
[TBL] [Abstract][Full Text] [Related]
12. Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study.
Costa AC; Joaquim HPG; Forlenza OV; Gattaz WF; Talib LL
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):483-488. PubMed ID: 31218445
[TBL] [Abstract][Full Text] [Related]
13. Plasma metabolic profiling of mild cognitive impairment and Alzheimer's disease using liquid chromatography/mass spectrometry.
Liu Y; Li N; Zhou L; Li Q; Li W
Cent Nerv Syst Agents Med Chem; 2014; 14(2):113-20. PubMed ID: 25515716
[TBL] [Abstract][Full Text] [Related]
14. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
[TBL] [Abstract][Full Text] [Related]
15. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
[TBL] [Abstract][Full Text] [Related]
16. Searching for predictive blood biomarkers: misfolded p53 in mild cognitive impairment.
Stanga S; Lanni C; Sinforiani E; Mazzini G; Racchi M
Curr Alzheimer Res; 2012 Dec; 9(10):1191-7. PubMed ID: 22746246
[TBL] [Abstract][Full Text] [Related]
17. Lymphocytic mitochondrial aconitase activity is reduced in Alzheimer's disease and mild cognitive impairment.
Mangialasche F; Baglioni M; Cecchetti R; Kivipelto M; Ruggiero C; Piobbico D; Kussmaul L; Monastero R; Brancorsini S; Mecocci P
J Alzheimers Dis; 2015; 44(2):649-60. PubMed ID: 25322927
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.
González-Domínguez R; García A; García-Barrera T; Barbas C; Gómez-Ariza JL
Electrophoresis; 2014 Dec; 35(23):3321-30. PubMed ID: 25136972
[TBL] [Abstract][Full Text] [Related]
20. Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease.
Waragai M; Yoshida M; Mizoi M; Saiki R; Kashiwagi K; Takagi K; Arai H; Tashiro J; Hashimoto M; Iwai N; Uemura K; Igarashi K
J Alzheimers Dis; 2012; 32(1):33-41. PubMed ID: 22751175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
